Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Blind

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Molecular Therapy. Nucleic Acids|January 24, 2017
Aptamer Selection Technology and Recent AdvancesMichael Blind, Michael Blank
Current Opinion in Chemical Biology|July 12, 2005
Aptamers as tools for target validationMichael Blank, Michael Blind
Current Opinion in Drug Discovery & Development|March 13, 2003
Aptamers and aptazymes: accelerating small molecule drug discoveryPetra Burgstaller, Andreas Jenne, Michael Blind
Drug Discovery Today|January 28, 2003
Aptamers as tools for target prioritization and lead identificationPetra Burgstaller, Anne Girod, Michael Blind
ACS Chemical Biology|September 4, 2014
An aptamer to the MAP kinase insert regionSabine Lennarz, Elena Heider, Michael Blind, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
MicrobodiesHans-Ulrich Schmoldt, Matin Daneschdar, Harald Kolmar, et al.
Chembiochem : a European Journal of Chemical Biology|July 4, 2009
A RNA-based approach towards small-molecule inhibitorsGünter Mayer, Dirk Faulhammer, Mira Grättinger, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2009
From selection to caged aptamers: identification of light-dependent ssDNA aptamers targeting cytohesinGünter Mayer, Andrea Lohberger, Sabine Butzen, et al.
Angewandte Chemie (International Ed. in English)|March 11, 2015
Selective aptamer-based control of intraneuronal signalingSabine Lennarz, Therese Christine Alich, Tony Kelly, et al.
Biochemical and Biophysical Research Communications|May 11, 2010
In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxinTzuu-Wang Chang, Michael Blank, Pavithra Janardhanan, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Molecular Therapy. Nucleic Acids|January 24, 2017
Aptamer Selection Technology and Recent AdvancesMichael Blind, Michael Blank
Current Opinion in Chemical Biology|July 12, 2005
Aptamers as tools for target validationMichael Blank, Michael Blind
Current Opinion in Drug Discovery & Development|March 13, 2003
Aptamers and aptazymes: accelerating small molecule drug discoveryPetra Burgstaller, Andreas Jenne, Michael Blind
Drug Discovery Today|January 28, 2003
Aptamers as tools for target prioritization and lead identificationPetra Burgstaller, Anne Girod, Michael Blind
ACS Chemical Biology|September 4, 2014
An aptamer to the MAP kinase insert regionSabine Lennarz, Elena Heider, Michael Blind, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
MicrobodiesHans-Ulrich Schmoldt, Matin Daneschdar, Harald Kolmar, et al.
Chembiochem : a European Journal of Chemical Biology|July 4, 2009
A RNA-based approach towards small-molecule inhibitorsGünter Mayer, Dirk Faulhammer, Mira Grättinger, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2009
From selection to caged aptamers: identification of light-dependent ssDNA aptamers targeting cytohesinGünter Mayer, Andrea Lohberger, Sabine Butzen, et al.
Angewandte Chemie (International Ed. in English)|March 11, 2015
Selective aptamer-based control of intraneuronal signalingSabine Lennarz, Therese Christine Alich, Tony Kelly, et al.
Biochemical and Biophysical Research Communications|May 11, 2010
In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxinTzuu-Wang Chang, Michael Blank, Pavithra Janardhanan, et al.
Pageof 2